Cevostamab in patients with heavily pretreated R/R myeloma: updated results from a Phase I trial

Alexander Lesokhin, MD, Memorial Sloan Kettering Cancer Center, New York, NY, presents the updated results of an ongoing Phase I study (NCT03275103) investigating cevostamab, a FcRH5xCD3 bispecific antibody, as monotherapy in patients with heavily pretreated relapsed/refractory (R/R) multiple myeloma (MM). Dr Lesokhin highlights that the findings of the results indicate clinically meaningful activity and manageable safety of the agent in this difficult-to-treat patient population. The recommended Phase II dose of cevostamab was determined to be 160 milligrams every three weeks, following a three-step-up dose regimen. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.